证券代码：300267 证券简称：尔康制药 公告编号：2025-038 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、投资概述 湖南尔康制药股份有限公司（以下简称"公司"）于 2025 年 10 月 29 日召 开第五届董事会第十六次会议，审议通过了《关于建设尔康尼日利亚注射剂生产 项目的议案》，同意公司全资孙公司尔康矿业尼日利亚有限公司使用自筹资金 800 万美元投资建设尔康尼日利亚注射剂生产项目（以下称"项目"或"本次投 资"）。 湖南尔康制药股份有限公司 关于建设尔康尼日利亚注射剂生产项目的公告 根据相关法律法规及《公司章程》的规定，本次事项经公司董事会审议通过 后，无需提交股东大会审议。本次事项不构成关联交易，不构成《上市公司重大 资产重组管理办法》规定的重大资产重组。 二、投资主体的基本情况 1、名称：尔康矿业尼日利亚有限公司 2、类型：股份有限公司（company limited by shares） 6、持股比例：公司通过全资子公司湖南尔康（香港）有限公司持有尔康矿 业尼日利亚有限公司 100%的股权。 三、项目基本情况 1、项目名称：尔康 ...

证券代码：300267 证券简称：尔康制药 公告编号：2025-031 湖南尔康制药股份有限公司 关于董事会换届选举的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 湖南尔康制药股份有限公司（以下简称"公司"）第五届董事会任期即将届 满，根据《公司法》、《深圳证券交易所创业板股票上市规则》、《深圳证券交 易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律法规、 规范性文件及《公司章程》等有关规定，公司决定按照相关法律程序进行董事会 换届选举。 一、董事会换届选举情况 公司于 2025 年 10 月 29 日召开第五届董事会第十六次会议，审议通过了《关 于董事会换届选举暨提名第六届董事会非独立董事候选人的议案》和《关于董事 会换届选举暨提名第六届董事会独立董事候选人的议案》。 公司第六届董事会 将由 7 名董事组成，其中非独立董事 4 名（含职工代表董事 1 名，职工代表董事 由职工代表大会选举产生，无需提交股东会审议），独立董事 3 名。 经公司第五届董事会提名委员会资格审查，公司第五届董事会同意提名帅放 文先生、施湘燕女士、孙庆荣先生 ...

证券代码：300267 证券简称：尔康制药 公告编号：2025-037 湖南尔康制药股份有限公司独立董事候选人声明与承诺 声明人吴勇作为湖南尔康制药股份有限公司第六届董事会独立董事候选 人，已充分了解并同意由提名人湖南尔康制药股份有限公司董事会提名为湖南 尔康制药股份有限公司（以下简称"该公司"）第六届董事会独立董事候选人。 现公开声明和保证，本人与该公司之间不存在任何影响本人独立性的关系，且 符合相关法律、行政法规、部门规章、规范性文件和深圳证券交易所业务规则 对独立董事候选人任职资格及独立性的要求，具体声明并承诺如下事项： 一、本人已经通过湖南尔康制药股份有限公司第五届董事会提名委员会或者 独立董事专门会议资格审查，提名人与本人不存在利害关系或者其他可能影响独 立履职情形的密切关系。 ☑ 是 □ 否 如否，请详细说明：_______________________________ 二、本人不存在《中华人民共和国公司法》第一百七十八条等规定不得担任 公司董事的情形。 ☑ 是 □ 否 如否，请详细说明：_______________________________ 三、本人符合中国证监会《上市公司独立董事管理 ...

证券代码：300267 证券简称：尔康制药 公告编号：2025-039 湖南尔康制药股份有限公司 关于召开 2025 年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东大会届次：2025 年第一次临时股东大会 2、股东大会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所创业板 股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运 作》等法律、行政法规、部门规章、规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 11 月 14 日 14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 11 月 14 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投票的 具体时间为 2025 年 11 月 14 日 9:15 至 15:00 的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 （2）公司董事、监事和 ...

证券代码：300267 证券简称：尔康制药 公告编号：2025-028 湖南尔康制药股份有限公司 第五届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 湖南尔康制药股份有限公司（以下简称"公司"）第五届董事会第十六次会 议于 2025 年 10 月 29 日在公司会议室以现场结合通讯表决的方式召开。本次会 议的通知于 2025 年 10 月 24 日以书面、邮件形式通知了全体董事。本次会议由 公司董事长帅放文先生主持，会议应参与表决的董事 7 名，实际参与表决的董事 7 名，本次会议的通知、召开以及参与人数均符合相关法律、法规及《公司章程》 的有关规定。 经全体董事认真审议，形成如下决议： 一、审议通过了《关于公司〈2025 年第三季度报告〉的议案》 经审议，董事会认为：公司 2025 年第三季度报告的编制程序、内容和格式 符合相关文件的规定；2025 年第三季度报告编制期间，未有泄密及其他违反法 律法规或损害公司利益的行为发生；公司的财务报告真实、准确、完整地反映了 公司的财务状况和经营成果，不存在任何虚假记载、误导性陈述或者重大 ...

Core Insights - The company reported a third-quarter revenue of 325 million yuan, representing a year-on-year growth of 39.32% [1] - The net profit for the third quarter was 1.9412 million yuan, showing a year-on-year increase of 106.11% [1] - For the first three quarters, the total revenue reached 1.006 billion yuan, with a year-on-year growth of 17.81% [1] - The net profit for the first three quarters was 39.5759 million yuan, reflecting a significant year-on-year increase of 255.40% [1]

Financial Performance - The company's revenue for Q3 2025 reached ¥324,541,963.43, representing a 39.32% increase compared to the same period last year[5] - Net profit attributable to shareholders was ¥1,941,249.06, a significant increase of 106.11% year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥2,211,584.10, up 106.43% from the previous year[5] - Basic earnings per share for the period were ¥0.0009, an increase of 105.84% year-on-year[5] - Total operating revenue for the current period reached ¥1,006,423,651.81, an increase of 17.8% compared to ¥854,289,240.97 in the previous period[22] - Net profit for the current period was ¥27,110,714.45, a significant recovery from a net loss of ¥26,889,704.70 in the previous period[23] - The profit attributable to shareholders of the parent company was ¥39,575,891.64, compared to a loss of ¥25,467,316.32 in the previous period[23] Cash Flow and Assets - The operating cash flow for the year-to-date period was ¥211,684,847.35, reflecting a 179.22% increase[5] - The company's cash and cash equivalents at the end of the reporting period amount to ¥709,202,365.93, an increase from ¥698,537,949.74 at the beginning of the period[19] - The total current assets are ¥1,774,063,309.93, compared to ¥1,717,081,656.36 at the beginning of the period, reflecting a growth of approximately 3.3%[20] - Total assets at the end of the reporting period were ¥5,202,672,968.23, a slight increase of 0.06% from the end of the previous year[5] - The ending balance of cash and cash equivalents was CNY 478,021,035.45, compared to CNY 453,787,274.52 in the previous period[25] Shareholder Information - The total number of common shareholders at the end of the reporting period is 49,105[15] - The largest shareholder, Shuai Fangwen, holds 41.38% of shares, totaling 853,574,906 shares, with 640,181,179 shares pledged[15] Expenses and Liabilities - The company reported a significant decrease in sales expenses by 41.33% to ¥4,268.68 due to reduced promotional costs[11] - Financial expenses increased by 286.16% to ¥353.66, primarily due to decreased exchange gains[11] - Total liabilities decreased slightly to ¥790,633,212.03 from ¥797,540,680.70, indicating a reduction of 0.9%[21] - Total operating costs amounted to ¥985,154,942.51, up from ¥893,553,175.63, reflecting a growth of 10.3%[22] Research and Development - Research and development expenses were ¥30,243,874.28, down from ¥34,116,241.19, showing a decrease of 11.1%[23] - The company has completed the writing of 3 new software copyrights and 2 invention patents, with one patent already receiving preliminary approval[17] Investments and Projects - The company is investing $10 million in a comprehensive formulation production project in Tanzania, expected to complete equipment debugging by Q4 2025[16] - A new company, Hengzhenglong Co., Ltd., has been established in Cambodia with a registered capital of $2 million to support business development[17] - The subsidiary, Hangzhou Land Intelligent Technology Co., Ltd., has applied for and obtained operating qualifications for various medical devices, enhancing its market position in AI technology applications[17] Comprehensive Income - Other comprehensive income after tax was reported at -¥17,720,724.55, an improvement from -¥85,012,752.50 in the previous period[23] - Total comprehensive income attributable to the parent company was CNY 21,715,433.97, a decrease of CNY 110,445,017.59 compared to the previous period[24]

Core Points - The company announced the approval of a proposal to sell its stock assets during the 11th Board Meeting and the first extraordinary shareholders' meeting in September 2025 [1] - The aim of the asset sale is to optimize the company's asset structure, focus on its main business, and release the value of certain assets [1] - The management is authorized to sell a total of 8,685,953 shares of Guizhou Yibai Pharmaceutical Co., Ltd., 970,605 shares of Aoyuan Optical Technology Co., Ltd., 7,716 shares of China Ping An Insurance (Group) Co., Ltd., and 4,712,205 shares of Hunan Erkang Pharmaceutical Co., Ltd. through centralized bidding, block trading, or a combination of both by December 31, 2025 [1] - The company has completed the sale of its holdings in Yibai Pharmaceutical, Aoyuan, Ping An, and Erkang Pharmaceutical [1]

Core Insights - Levodopa is a key medication for treating Parkinson's disease, alleviating symptoms such as muscle stiffness, tremors, and slow movement. It also shows potential for treating Alzheimer's disease, chronic pain, and constipation, with broad applications in biomedical and materials science fields [1][3][4]. Industry Overview - The levodopa market has seen continuous growth in demand due to an aging population and increasing Parkinson's disease cases. The market was negatively impacted by the pandemic from 2020 to 2022, but sales began to recover in 2023, reaching 31.83 million yuan in 2024 [1][7][8]. Industry Chain - The levodopa industry chain consists of upstream suppliers of chemical raw materials and excipients, midstream research and manufacturing processes, and downstream applications in medical institutions, pharmacies, and patients. The number of Parkinson's patients significantly influences the industry's development, with over 3 million patients aged 65 and above in China [6][7]. Competitive Landscape - The global levodopa market is dominated by a few large pharmaceutical companies, such as Merck & Co. and Pfizer, while domestic companies primarily focus on generic drugs. Key players in China include Shandong Xinhua Pharmaceutical Co., Zhejiang Huahai Pharmaceutical Co., and others [8][9]. Industry Development Trends - Market demand for levodopa is expected to continue increasing due to the rising incidence of Parkinson's disease and improvements in healthcare systems in emerging countries [10]. - Technological advancements in biopharmaceuticals are likely to enhance levodopa production processes, leading to improved efficiency and product quality. Companies are expected to develop various formulations, such as sustained-release and controlled-release preparations, to enhance patient experience [11]. - The globalization of the levodopa industry presents opportunities for companies to expand into international markets, increasing brand recognition and competitiveness [12].

Group 1 - Double-Helix Pharmaceutical announced that its associate, Changfeng Pharmaceutical, is expected to be listed on the Hong Kong Stock Exchange on October 8, 2025, with a global offering of 41.198 million shares priced at HKD 14.75 each. Double-Helix holds approximately 3.68% of Changfeng's shares, with a lock-up period of 12 months post-listing [1] - Changfeng Pharmaceutical is involved in the pharmaceutical industry, specifically in the research and development of gene-engineered drugs [2] Group 2 - Lio Corporation has submitted an application to the Hong Kong Stock Exchange for issuing H-shares and listing on the main board [3] - Lio Corporation operates in the mechanical manufacturing and digital marketing sectors [3] Group 3 - Changjiang Securities received approval from the China Securities Regulatory Commission to issue corporate bonds totaling no more than CNY 20 billion, valid for 24 months [4] - Changjiang Securities provides services such as securities and futures brokerage, financial product distribution, investment advisory, asset custody, and margin financing [4] Group 4 - Jingye Intelligent plans to acquire 51% of Hefei Shengwen Information Technology for CNY 108 million, focusing on engineering information technology and intelligent products [5][6] - Jingye Intelligent specializes in the research, development, production, and sales of special robots and intelligent equipment systems [6] Group 5 - Aimeike's subsidiary received approval for the registration of Minoxidil topical solution, a non-prescription drug for treating hair loss [7][8] - Aimeike is engaged in the research, development, production, and sales of biomedical materials and biopharmaceuticals [8] Group 6 - Dalian Heavy Industry expects a net profit of CNY 474 million to CNY 508 million for the first three quarters of 2025, representing a year-on-year increase of 19.91% to 28.52% [9] - Dalian Heavy Industry specializes in the design, manufacturing, assembly, and installation of major technical equipment [9] Group 7 - Huayou Cobalt signed supply agreements with LGES for a total of approximately 76,000 tons of ternary precursor products from 2026 to 2030 [10][11] - Huayou Cobalt focuses on the research, manufacturing, and sales of new energy lithium battery materials and cobalt new materials [11] Group 8 - Zhenjiang Co. plans to reduce its shareholding by up to 5.529 million shares, not exceeding 3% of the total share capital, due to personal funding needs [12] - Zhenjiang Co. is involved in the design, processing, and sales of wind power equipment and components [12] Group 9 - Watson Bio's subsidiary received a drug registration certificate for a 13-valent pneumococcal polysaccharide conjugate vaccine for children [14][15] - Watson Bio specializes in the research, development, production, and sales of human vaccines and biopharmaceuticals [15] Group 10 - Yikang Pharmaceutical's major shareholder plans to reduce holdings by up to 42 million shares, not exceeding 2.04% of the total share capital, due to personal funding needs [16] - Yikang Pharmaceutical is engaged in the production and sales of excipients, raw materials, finished drugs, and new energy materials [16] Group 11 - Sichuan Gold's shareholder plans to reduce holdings by up to 7.56 million shares, accounting for 1.80% of the total share capital [19] - Sichuan Gold focuses on the construction, mining, and sales of gold mines [19] Group 12 - Kangchen Pharmaceutical received approval for a clinical trial of an innovative drug for treating advanced esophageal squamous cell carcinoma [20][21] - Kangchen Pharmaceutical specializes in the manufacturing of chemical drug formulations [21] Group 13 - UCloud plans to repurchase shares worth between CNY 8 million and CNY 10 million for employee stock ownership plans [22] - UCloud provides cloud computing services centered on IT infrastructure [22] Group 14 - Woton Technology announced an adjustment to its share repurchase plan, raising the price cap to CNY 60 per share [24] - Woton Technology specializes in the research, manufacturing, and sales of separation membrane products [24] Group 15 - Five Continents Medical announced plans for shareholders to reduce holdings by up to 126,530 shares, accounting for 1.8606% of the total share capital [26] - Five Continents Medical focuses on the research, manufacturing, and sales of disposable sterile infusion medical devices [26] Group 16 - CIMC Group plans to repurchase A-shares with a total amount not exceeding CNY 5 billion [27] - CIMC Group specializes in logistics and energy equipment solutions [27] Group 17 - Zhifei Biological's subsidiary received a drug registration certificate for a trivalent influenza vaccine suitable for individuals aged 3 and above [29][30] - Zhifei Biological is involved in the research, development, production, and sales of vaccines and biological products [30]